McGonigle R J, Weston M J, Keenan J, Jackson D B, Parsons V
Magnesium. 1984;3(1):1-7.
This study was designed to assess the influence of magnesium on circulating plasma immunoreactive parathyroid hormone (iPTH) in end-stage renal disease. 20 patients receiving regular hemodialysis therapy underwent plasma measurements of iPTH and 25-hydroxycholecalciferol (25-OHCC) concentrations before and 10 weeks after the magnesium concentration in the dialysate was increased from 0.75 to 1.50 mmol/l. This resulted in a 36% rise in the mean predialysis plasma magnesium concentration from 1.25 to 1.70 mmol/l (p less than 0.001) and a 23% fall in the mean plasma iPTH concentration from 546 to 418 ng/l (p less than 0.001). Mean plasma concentrations for calcium, phosphate, and 25-OHCC also decreased, but these changes were not significant. In conclusion, we have demonstrated that a rise in plasma magnesium concentration from elevated to significantly higher levels reduces circulating plasma iPTH in normocalcemic uremic patients with initially both normal and raised plasma PTH levels.
本研究旨在评估镁对终末期肾病患者循环血浆免疫反应性甲状旁腺激素（iPTH）的影响。20例接受常规血液透析治疗的患者，在透析液中镁浓度从0.75 mmol/l提高到1.50 mmol/l之前及之后10周，分别进行了iPTH和25-羟胆钙化醇（25-OHCC）血浆浓度测定。这使得透析前血浆镁平均浓度从1.25 mmol/l上升36%至1.70 mmol/l（p<0.001），血浆iPTH平均浓度从546 ng/l下降23%至418 ng/l（p<0.001）。钙、磷和25-OHCC的血浆平均浓度也有所下降，但这些变化不显著。总之，我们已经证明，在最初血浆PTH水平正常和升高的血钙正常的尿毒症患者中，血浆镁浓度从升高水平升至显著更高水平会降低循环血浆iPTH。
